Three Ways to Damage DNA: Alkylation, Crosslinking, and Topoisomerase Trapping | Visual AI Learning Guide

Look at the three panels as three different ways of leaving a mark on DNA. In the first, an alkylating agent has attached a small chemical group to a guanine base — a monofunctional adduct. If the drug has two reactive ends, it can grab two sites at once, and when those sites sit on opposite strands you get an interstrand crosslink, a covalent staple holding the duplex together. Cisplatin reaches the same endpoint by a different route: its platinum center loses its chlorides, becomes reactive, and links two adjacent guanines on the same strand, bending the helix. The third panel is the odd one out. Here the DNA is broken, but a topoisomerase enzyme is still covalently attached to the broken end. That is the trapped cleavage complex. Notice that in the first two panels the drug is the lesion; in the third, the drug has turned a normal, transient enzyme intermediate into a persistent one.

0:00 / 0:00

Auto-play

DNA-damaging chemotherapeutics fall into three mechanistically distinct groups, and the distinction matters because each produces a different kind of lesion with a different consequence.

Alkylating agents are electrophiles that transfer an alkyl group to a nucleophilic site on a DNA base. The most reactive positions are the N7 and O6 of guanine, and the N3 of adenine. A monofunctional alkylator adds one group and produces a base adduct that can mispair during replication. A bifunctional alkylator, such as cyclophosphamide's active metabolite phosphoramide mustard or chlorambucil, carries two reactive groups and can react twice, linking two nucleophilic sites. When the two sites are on opposite strands, the result is an interstrand crosslink, a covalent bridge that holds the two strands together. When they are on the same strand, the result is an intrastrand crosslink or an intrastrand adduct.

Platinum coordination complexes, principally cisplatin, carboplatin, and oxaliplatin, are not alkylators in the strict chemical sense, but they produce the same functional lesion. Cisplatin's square-planar platinum(II) center carries two labile chloride leaving groups. Inside the cell, where chloride concentration is low, water displaces the chlorides and the activated platinum coordinates to the N7 of two adjacent guanines, forming a 1,2-intrastrand crosslink that bends and unwinds the helix. Roughly 90 percent of cisplatin adducts are of this intrastrand type, with interstrand crosslinks a minority. The chemistry differs from an alkylator; the biological consequence — a covalent, helix-distorting bridge — does not.

Topoisomerase poisons work by an entirely different principle. Topoisomerase I nicks one strand, allows it to rotate around the intact strand, and religates it; topoisomerase II cuts both strands, passes another duplex through the gap, and religates. Both enzymes form a transient covalent tyrosyl–phosphate bond to the DNA as part of the normal catalytic cycle. A poison such as irinotecan's active metabolite SN-38 (topoisomerase I) or etoposide (topoisomerase II) intercalates at the enzyme–DNA interface and stabilizes the cleavage complex, slowing religation. The strand break, normally transient, becomes persistent and protein-linked. This is the crucial distinction from a simple DNA binder: a poison does not merely occupy the helix, it traps the enzyme in a state the cell must actively resolve.